Longevity & AgingResearch PaperOpen Access

Psychedelics and Parkinson's Share Surprising Visual Hallucination Pathways

A new review finds striking overlaps in how psychedelics and Lewy body diseases generate visual hallucinations, pointing to shared brain mechanisms.

Monday, October 5, 2026 0 views
Published in Schizophr Bull
Glowing neural pathways branching through a translucent human brain, with serotonin receptor molecules illuminated in violet and gold.

Summary

Researchers from the International Consortium on Hallucinations Research conducted a narrative review comparing visual hallucinations (VH) in Lewy body diseases (LBDs) — including Parkinson's disease and dementia with Lewy bodies — with those induced by serotonergic psychedelics like psilocybin and LSD. Despite vastly different causes, both conditions produce strikingly similar hallucinatory phenomena, from illusory motion and pareidolia to complex entity encounters. Both share a common cortical signature: hyperactive associative cortex paired with hypoactive sensory cortex. Crucially, the serotonin 2A receptor (5-HT2AR) appears central to both, with psychedelics activating it and LBD patients showing receptor upregulation correlated with more hallucinations. These findings suggest psychedelics could serve as a controlled research model for understanding and eventually treating hallucinations in neurodegenerative disease.

Detailed Summary

Visual hallucinations (VH) are among the most distressing and clinically significant symptoms of Lewy body diseases (LBDs), including Parkinson's disease (PD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB). They predict earlier institutionalization, caregiver burden, and reduced quality of life. Separately, serotonergic psychedelics (SPs) such as psilocybin, LSD, mescaline, DMT, and DOI reliably induce VH in healthy individuals. This review from the International Consortium on Hallucinations Research systematically compares these two phenomena across phenomenology, cortical neuroscience, and serotonergic mechanisms.

Phenomenologically, both LBDs and SPs produce a spectrum of visual disturbances. Metamorphopsias — distortions of color, shape, size, or motion — are reported in roughly 75% of PD patients and are a hallmark of psychedelic experience. Minor hallucinations, including passage hallucinations, pareidolia, and misidentification illusions, occur in 42% of newly diagnosed LBD patients and are also documented, though underappreciated, in psychedelic experience reports. Complex hallucinations involving entities, animals, or transformed scenes occur in 22–38% of LBD patients and are central to psychedelic phenomenology. Notably, illusory motion (kinetopsia) appears in ~25% of PD patients and is a defining feature of psychedelic states, with converging psychophysical evidence implicating impaired global-motion integration in the middle temporal (MT) cortex in both groups.

At the cortical level, neuroimaging studies reveal a shared signature: hyperactivation of associative and frontal cortices alongside hypoactivation of primary sensory cortices. This pattern — reduced visual evoked responses combined with a shift toward cortical excitation — is observed in both LBD patients during hallucinations and in healthy subjects under psychedelics. Reduced responsiveness of early visual areas may cause the brain to rely more heavily on top-down, generative processing, effectively allowing internally generated percepts to dominate perception.

The serotonin 2A receptor (5-HT2AR) is a critical convergence point. SP-induced hallucinations are primarily mediated through 5-HT2AR (and modulated by 5-HT1AR) activation. In LBDs, 5-HT2AR upregulation correlates with greater hallucination frequency, and its pharmacological blockade — most notably with pimavanserin, an approved 5-HT2AR inverse agonist — significantly reduces VH in these patients. This pharmacological symmetry strongly supports a shared neuromodulatory mechanism.

The authors propose that sensory degradation (from neurodegeneration or pharmacological dampening of sensory cortex) combined with cortical excitation creates conditions permissive to hallucination in both contexts. Psychedelics, by providing a controlled, reversible, and dose-titratable induction of similar phenomena in healthy adults, could serve as a powerful model system for developing LBD hallucination biomarkers and testing interventions. Future research priorities include real-time neuroimaging of discrete hallucinatory episodes and rigorous psychophysical paradigms targeting phenomena common to both conditions, such as illusory motion.

Key Findings

  • Both LBDs and serotonergic psychedelics produce overlapping VH including illusory motion, pareidolia, passage hallucinations, and entity encounters.
  • A shared cortical signature emerges: hyperactive associative cortex and hypoactive primary sensory cortex in both conditions.
  • The serotonin 2A receptor (5-HT2AR) is implicated in both SP-induced hallucinations and LBD hallucinations, with upregulation correlating to VH severity.
  • Pimavanserin, a 5-HT2AR inverse agonist, reduces hallucinations in LBD, mirroring the receptor's role in psychedelic phenomenology.
  • Impaired global-motion integration in middle temporal cortex may underlie illusory motion (kinetopsia) in both PD patients and psychedelic users.

Methodology

This is a narrative review synthesizing literature from neurology, cognitive neuroscience, and systems neuroscience. The authors drew on human neuroimaging studies, animal models, psychophysical experiments, and clinical pharmacology trials. No primary data were collected; findings represent a qualitative synthesis of existing evidence.

Study Limitations

As a narrative review, the synthesis is subject to selection bias and does not provide quantitative effect sizes. Direct cross-condition comparisons are complicated by differences in disease duration, cognitive status, and medication confounds in LBD patients versus the controlled settings of psychedelic studies. Many phenomenological parallels rely on anecdotal or qualitative psychedelic experience reports rather than structured clinical assessments.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: